NEW YORK (GenomeWeb) – Swedish biotech firm Alligator Bioscience has expanded a collaboration with Stanford University in the area of immuno-oncology biomarker discovery.
As part of the agreement, the partners aim to enable the early prediction of clinical efficacy of Alligator's pipeline candidates by analyzing potential systemic biomarkers, which may eventually benefit patients through appropriate treatment selection based on biomarker analysis.
Alligator, based in Lund, is working with the laboratory of Stanford professor Dean Felsher, and expert in the field of oncogene-induced cancer immune evasion and the relationship between oncogenes and cancer immunotherapy. The lab's expertise in RNA sequencing and proteomic analysis is key to the partnership, Alligator said.
"The expanded collaboration with Stanford University will accelerate the pre-clinical development of our pipeline projects and strengthen the biomarker discovery program by drawing on their world-leading expertise in this area", Per Norlén, CEO of Alligator Bioscience, said in a statement.